Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Curevac N.V. (NQ: CVAC )

2.840 +0.010 (+0.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Curevac N.V.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron... 
From CureVac
Via AccessWire
Exposures COVID-19
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
Via Benzinga
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK - Five-year contract enables production of up to 80 million... 
From CureVac
Via AccessWire
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
Via Benzinga
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
- Phase 1 dose-escalation study started at clinical sites in the U.S. - Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine... 
From CureVac
Via AccessWire
Exposures COVID-19
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
- The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics - CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate... 
From CureVac
Via AccessWire
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We've got another busy day of trading ahead of us and we're starting with the biggest pre-market stock movers for Tuesday! 
Via InvestorPlace
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad... 
From CureVac
Via AccessWire
53 Biggest Movers From Friday
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle... 
Via Benzinga
CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?
Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade. 
Via InvestorPlace
34 Stocks Moving In Friday's Mid-Day Session
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91.... 
Via Benzinga
BofA Downgrades CureVac On Limited 2022 Prospects
There is limited upside from CureVac BV’s (NASDAQ:CVAC 
Via Benzinga
Chopped Stocks
The day's theme is sell tech and buy banks. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022
Upgrades According to Seaport Global, the prior rating for KB Home (NYSE: 
Via Benzinga
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE: 
Via Benzinga
52 Biggest Movers From Friday
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its... 
Via Benzinga
30 Stocks Moving In Friday's Mid-Day Session
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5.... 
Via Benzinga
dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V.
BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für... 
From dievini Hopp BioTech holding GmbH & Co. KG
Via AccessWire
CureVac Outlines Upcoming Catalysts For Vaccine Programs
Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs. CureVac's preclinical second-... 
Via Benzinga
The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO
The omicron variant signals a need for annual Covid shots, BioNTech's CEO said. 
Via Investor's Business Daily
CureVac (CVAC) Q3 2021 Earnings Call Transcript
CVAC earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
56 Biggest Movers From Friday
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on... 
Via Benzinga
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
- Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review - Nature publication of... 
From CureVac
Via AccessWire
Topics Death Intellectual Property Regulatory Compliance
Exposures COVID-19 Death Intellectual Property
48 Stocks Moving In Friday's Mid-Day Session
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded... 
Via Benzinga
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions - Expansion part of Phase 1 study fully recruited;... 
From CureVac
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.